At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 112 enrolled
Drug / intervention
terlipressin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III Study of Intravenous Terlipressin in Patients With Hepatorenal Syndrome Type 1
In Brief
A Phase 3 clinical trial evaluating terlipressin and Placebo for Hepatorenal Syndrome. Completed, enrolled 112 participants across 37 sites.
Detailed Summary
The purpose of this study is to determine whether terlipressin is safe and effective in the treatment of patients with hepatorenal syndrome (HRS) type 1 when compared to placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatorenal Syndrome
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2004
First PostedAug 2004
Primary CompletionMar 2006
Study CompletionSep 2006
TodayJul 2026
First PostedAug 9, 2004
Enrollment StartJun 1, 2004
Primary CompletionMar 1, 2006
Study CompletionSep 1, 2006
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 21.9 years ago
Interventions
terlipressindrug
Placebodrug